Maj Vinberg

List of Publications by Year
in descending order

233 papers	8,824 citations	50276 46 h-index	60623 81 g-index
256 all docs	256 docs citations	256 times ranked	8852 citing authors

#	Article	IF	Citations
1	Socio-economic functioning in patients with bipolar disorder and their unaffected siblings â€“ results from a nation-wide population-based longitudinal study. Psychological Medicine, 2023, 53, 706-713.	4.5	18
2	Association between lifetime and recent stressful life events and the early course and psychopathology in patients with newly diagnosed bipolar disorder, firstâ€degree unaffected relatives and healthy controls: Crossâ€sectional results from a prospective study. Bipolar Disorders, 2022, 24, 59-68.	1.9	2
3	Physical health status in first-degree relatives of patients with bipolar disorder, a systematic review. Nordic Journal of Psychiatry, 2022, 76, 433-441.	1.3	1
4	Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain, Behavior, and Immunity, 2022, 101, 93-135.	4.1	670
5	Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2022, 300, 449-461.	4.1	34
6	At the Core of Depression: A Diagnostic Interview of the Core Features of Depression. Psychopathology, 2022, 55, 219-225.	1.5	1
7	Discriminating between patients with unipolar disorder, bipolar disorder, and healthy control individuals based on voice features collected from naturalistic smartphone calls. Acta Psychiatrica Scandinavica, 2022, 145, 255-267.	4.5	2
8	Socio-economic status and functioning in patients newly diagnosed with bipolar disorder and their unaffected siblings - Results from a cross-sectional clinical study. Journal of Affective Disorders, 2022, 310, 404-411.	4.1	7
9	Neural underpinnings of emotion regulation subgroups in remitted patients with recently diagnosed bipolar disorder. European Neuropsychopharmacology, 2022, 60, 7-18.	0.7	6
10	Differential trajectory of cognitive functions in neurocognitive subgroups of newly diagnosed patients with bipolar disorder and their unaffected first-degree relatives â€" A longitudinal study. Journal of Affective Disorders, 2022, 311, 115-125.	4.1	3
11	Affective disorders: eliminate WArning signs and REstore functioningâ€"AWAREâ€"a randomised controlled multimodule intervention study, presentation of design and intervention. BMJ Open, 2022, 12, e058839.	1.9	0
12	Trajectory of aberrant reward processing in patients with bipolar disorder â€" A longitudinal fMRI study. Journal of Affective Disorders, 2022, 312, 235-244.	4.1	4
13	Effect of Actionâ€Based Cognitive Remediation on cognitive impairment in patients with remitted bipolar disorder: A randomized controlled trial. Bipolar Disorders, 2021, 23, 487-499.	1.9	31
14	Mood, activity, and sleep measured via daily smartphone-based self-monitoring in young patients with newly diagnosed bipolar disorder, their unaffected relatives and healthy control individuals. European Child and Adolescent Psychiatry, 2021, 30, 1209-1221.	4.7	6
15	Reduced frontostriatal response to expected value and reward prediction error in remitted monozygotic twins with mood disorders and their unaffected high-risk co-twins. Psychological Medicine, 2021, 51, 1637-1646.	4.5	9
16	Hippocampal subfield morphology in monozygotic twins discordant for affective disorders. Neuropsychopharmacology, 2021, 46, 561-568.	5.4	4
17	Cognitive processing of infant stimuli in pregnant women with and without affective disorders and the association to postpartum depression. European Neuropsychopharmacology, 2021, 42, 97-109.	0.7	6
18	Daily mobility patterns in patients with bipolar disorder and healthy individuals. Journal of Affective Disorders, 2021, 278, 413-422.	4.1	16

#	Article	IF	Citations
19	A nationwide populationâ€based longitudinal study mapping psychiatric disorders during lifetime in siblings to patients with bipolar disorder. Acta Psychiatrica Scandinavica, 2021, 143, 284-293.	4.5	11
20	Residual Anxiety in Patients with Bipolar Disorder in Full or Partial Remission: Metacognitive Beliefs and Neurocognitive Function. Cognitive Therapy and Research, 2021, 45, 179-189.	1.9	1
21	The impact of the trajectory of bipolar disorder on global cognitive function: A one-year clinical prospective case-control study. Journal of Affective Disorders, 2021, 278, 189-198.	4.1	10
22	Neurocognitive heterogeneity in patients with bipolar disorder and their unaffected relatives: associations with emotional cognition. Psychological Medicine, 2021, 51, 668-679.	4.5	26
23	Suicidal behaviour and bipolar disorder. , 2021, , 293-300.		0
24	Brain-derived neurotrophic factor levels in newly diagnosed patients with bipolar disorder, their unaffected first-degree relatives and healthy controls. BJPsych Open, 2021, 7, e55.	0.7	9
25	P.319 Cognitive predictors of mood episodes in patients newly diagnosed with bipolar disorder. European Neuropsychopharmacology, 2021, 44, S52-S53.	0.7	0
26	Intrauterine testosterone exposure and depression risk in opposite-sex and same-sex twins, a Danish register study. Psychological Medicine, 2021, , 1-6.	4.5	0
27	Peripheral inflammatory biomarkers define biotypes of bipolar depression. Molecular Psychiatry, 2021, 26, 3395-3406.	7.9	19
28	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. Journal of Affective Disorders, 2021, 282, 160-164.	4.1	24
29	Affective and non-affective cognition in patients with bipolar disorder type I and type II in full or partial remission: Associations with familial risk. Journal of Affective Disorders, 2021, 283, 207-215.	4.1	4
30	Associations between the cortisol awakening response and patient-evaluated stress and mood instability in patients with bipolar disorder: an exploratory study. International Journal of Bipolar Disorders, 2021, 9, 8.	2.2	7
31	A nation-wide population-based longitudinal study mapping physical diseases in patients with bipolar disorder and their siblings. Journal of Affective Disorders, 2021, 282, 18-25.	4.1	22
32	Strategies to Prolong Ketamineâ€™s Efficacy in Adults with Treatment-Resistant Depression. Advances in Therapy, 2021, 38, 2795-2820.	2.9	19
33	Impact of modification to DSM-5 criterion A for hypomania/mania in newly diagnosed bipolar patients: findings from the prospective BIO study. International Journal of Bipolar Disorders, 2021, 9, 14.	2.2	4
34	Higher systemic oxidatively generated DNA and RNA damage in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Free Radical Biology and Medicine, 2021, 168, 226-233.	2.9	12
35	Peripheral Inflammatory Biomarkers Define Biotypes of Bipolar Depression. Biological Psychiatry, 2021, 89, S156.	1.3	2
36	Prevalences of comorbid anxiety disorder and daily smartphone-based self-reported anxiety in patients with newly diagnosed bipolar disorder. Evidence-Based Mental Health, 2021, 24, 137-144.	4.5	2

#	Article	IF	Citations
37	Affective disorders impact prevalence of Flavonifractor and abundance of Christensenellaceae in gut microbiota. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110300.	4.8	15
38	Automatically Generated Smartphone Data in Young Patients With Newly Diagnosed Bipolar Disorder and Healthy Controls. Frontiers in Psychiatry, 2021, 12, 559954.	2.6	3
39	Emotional cognition subgroups in mood disorders: Associations with familial risk. European Neuropsychopharmacology, 2021, 51, 71-83.	0.7	9
40	A nation-wide population-based longitudinal study on life expectancy and cause specific mortality in patients with bipolar disorder and their siblings. Journal of Affective Disorders, 2021, 294, 472-476.	4.1	12
41	Affective episodes in recently diagnosed patients with bipolar disorder associated with altered working memory-related prefrontal cortex activity: A longitudinal fMRI study. Journal of Affective Disorders, 2021, 295, 647-656.	4.1	8
42	Effect of specialised versus generalised outpatient treatment for bipolar disorder: the CAG Bipolar trial - study protocol for a randomised controlled trial. BMJ Open, 2021, 11, e048821.	1.9	3
43	Voice analyses using smartphone-based data in patients with bipolar disorder, unaffected relatives and healthy control individuals, and during different affective states. International Journal of Bipolar Disorders, 2021, 9, 38.	2.2	7
44	Physical Health Profile and Associated Behavior During the COVID-19 Pandemic in Patients With Bipolar Disorder. Frontiers in Psychiatry, 2021, 12, 759694.	2.6	5
45	P.0717 Differential trajectory of cognitive functions in neurocognitive subgroups of newly diagnosed patients with bipolar disorder and their unaffected first-degree relatives. European Neuropsychopharmacology, 2021, 53, S524-S525.	0.7	0
46	P.0077 Higher systemic oxidatively generated DNA and RNA damage in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. European Neuropsychopharmacology, 2021, 53, S54-S55.	0.7	0
47	The effect of smartphone-based monitoring on illness activity in bipolar disorder: the MONARCA II randomized controlled single-blinded trial. Psychological Medicine, 2020, 50, 838-848.	4.5	75
48	Aberrant cognition in newly diagnosed patients with bipolar disorder and their unaffected relatives. Psychological Medicine, 2020, 50, 1808-1819.	4.5	22
49	Are remitted affective disorders and familial risk of affective disorders associated with metabolic syndrome, inflammation and oxidative stress? â€“ a monozygotic twin study. Psychological Medicine, 2020, 50, 1736-1745.	4.5	12
50	Automatically generated smartphone data and subjective stress in healthy individuals â€“ a pilot study. Nordic Journal of Psychiatry, 2020, 74, 293-300.	1.3	2
51	P.298 Emotional cognition heterogeneity in patients with mood disorders and clinical implication. European Neuropsychopharmacology, 2020, 40, S170-S171.	0.7	0
52	Bipolar disorders. Lancet, The, 2020, 396, 1841-1856.	13.7	419
53	Searching for the Needles in a Haystack; Is It Needless? The Search for Peripheral Biomarkers in Psychiatry. Frontiers in Psychiatry, 2020, 11, 689.	2.6	3
54	Daily self-reported and automatically generated smartphone-based sleep measurements in patients with newly diagnosed bipolar disorder, unaffected first-degree relatives and healthy control individuals. Evidence-Based Mental Health, 2020, 23, 146-153.	4.5	6

#	Article	IF	Citations
55	Impact of pretreatment interhemispheric hippocampal asymmetry on improvement in verbal learning following erythropoietin treatment in mood disorders: a randomized controlled trial. Journal of Psychiatry and Neuroscience, 2020, 45, 198-205.	2.4	5
56	Validity and characteristics of patient-evaluated adherence to medication via smartphones in patients with bipolar disorder: exploratory reanalyses on pooled data from the MONARCA I and II trials. Evidence-Based Mental Health, 2020, 23, 2-7.	4.5	4
57	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disorders, 2020, 22, 831-840.	1.9	40
58	S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders. Journal of Affective Disorders, 2020, 274, 726-732.	4.1	4
59	Transcranial pulsed electromagnetic fields for treatment-resistant depression: A multicenter 8-week single-arm cohort study. European Psychiatry, 2020, 63, e18.	0.2	9
60	Hypomania/Mania by DSM-5 definition based on daily smartphone-based patient-reported assessments. Journal of Affective Disorders, 2020, 264, 272-278.	4.1	6
61	Misinformed, misconducted, misguided and misrepresented metaâ€analyses. The use of antidepressants (AD) in major depressive disorders (MDD). Bipolar Disorders, 2020, 22, 862-863.	1.9	0
62	Mood instability in patients with newly diagnosed bipolar disorder, unaffected relatives, and healthy control individuals measured daily using smartphones. Journal of Affective Disorders, 2020, 271, 336-344.	4.1	23
63	Abnormal prefrontal cortex processing of reward prediction errors in recently diagnosed patients with bipolar disorder and their unaffected relatives. Bipolar Disorders, 2020, 22, 849-859.	1.9	4
64	Sleep and physical activity in patients with newly diagnosed bipolar disorder in remission, their first-degree unaffected relatives and healthy controls. International Journal of Bipolar Disorders, 2020, 8, 16.	2.2	10
65	Smartphone-based activity measurements in patients with newly diagnosed bipolar disorder, unaffected relatives and control individuals. International Journal of Bipolar Disorders, 2020, 8, 32.	2.2	17
66	Development and implementation of guidelines for the management of depression: a systematic review. Bulletin of the World Health Organization, 2020, 98, 683-697H.	3.3	25
67	High-sensitive C-reactive protein and homocysteine levels in patients with newly diagnosed bipolar disorder, their first-degree relatives, and healthy control personsâ€"Results from a clinical study. European Psychiatry, 2020, 63, e103.	0.2	2
68	Patient-evaluated cognitive function measured with smartphones and the association with objective cognitive function, perceived stress, quality of life and function capacity in patients with bipolar disorder. International Journal of Bipolar Disorders, 2020, 8, 31.	2.2	5
69	Is aberrant affective cognition an endophenotype for affective disorders? â€" A monozygotic twin study. Psychological Medicine, 2019, 49, 987-996.	4.5	12
70	A randomized placeboâ€controlled trial examining the effects of escitalopram on neuroticism and state anxiety in a nonclinical sample. Human Psychopharmacology, 2019, 34, e2711.	1.5	1
71	The validity of daily patient-reported anxiety measured using smartphones and the association with stress, quality of life and functioning in patients with bipolar disorder. Journal of Affective Disorders, 2019, 257, 100-107.	4.1	9
72	Whole-Brain Exploratory Analysis of Functional Task Response Following Erythropoietin Treatment in Mood Disorders: A Supervised Machine Learning Approach. Frontiers in Neuroscience, 2019, 13, 1246.	2.8	2

#	Article	IF	Citations
73	Differences in mood instability in patients with bipolar disorder type I and II: a smartphone-based study. International Journal of Bipolar Disorders, 2019, 7, 5.	2.2	29
74	Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. International Journal of Bipolar Disorders, 2019, 7, 8.	2.2	39
75	Is smartphoneâ€based mood instability associated with stress, quality of life, and functioning in bipolar disorder?. Bipolar Disorders, 2019, 21, 611-620.	1.9	32
76	Thirty-year cardiovascular risk in patients with newly diagnosed bipolar disorder and their healthy first-degree relatives. European Neuropsychopharmacology, 2019, 29, S347-S348.	0.7	1
77	Hormones, Emotional processing and prepartum Attachment in Pregnant women with Affective Disorders (HEAPAD). European Neuropsychopharmacology, 2019, 29, S382.	0.7	0
78	The association between mixed symptoms, irritability and functioning measured using smartphones in bipolar disorder. Acta Psychiatrica Scandinavica, 2019, 139, 443-453.	4.5	12
79	P.4.08 Metabolic syndrome, inflammation and oxidative stress as potential risk factors for affective disorders â€“ a twin study. European Neuropsychopharmacology, 2019, 29, S706-S707.	0.7	0
80	P.654 Central oxidative stress of RNA damage in patients with bipolar disorder and healthy control individuals. A prospective longitudinal case-control study. European Neuropsychopharmacology, 2019, 29, S444.	0.7	0
81	P.357 S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders. European Neuropsychopharmacology, 2019, 29, S255.	0.7	0
82	Cerebrospinal fluid oxidative stress metabolites in patients with bipolar disorder and healthy controls: a longitudinal case-control study. Translational Psychiatry, 2019, 9, 325.	4.8	31
83	The BDNF Val66Met Polymorphism Has No Effect on Encoding-Related Hippocampal Response But Influences Recall in Remitted Patients With Bipolar Disorder. Frontiers in Psychiatry, 2019, 10, 845.	2.6	2
84	Emotional Mental Imagery Abnormalities in Monozygotic Twins With, at High-Risk of, and Without Affective Disorders: Present in Affected Twins in Remission but Absent in High-Risk Twins. Frontiers in Psychiatry, 2019, 10, 801.	2.6	5
85	The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. European Neuropsychopharmacology, 2019, 29, 137-146.	0.7	19
86	Neural response during emotion regulation in monozygotic twins at high familial risk of affective disorders. NeuroImage: Clinical, 2019, 21, 101598.	2.7	34
87	A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder. Acta Psychiatrica Scandinavica, 2019, 139, 227-236.	4.5	23
88	Objective smartphone data as a potential diagnostic marker of bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2019, 53, 119-128.	2.3	66
89	Remitted affective disorders and high familial risk of affective disorders associate with aberrant intestinal microbiota. Acta Psychiatrica Scandinavica, 2019, 139, 174-184.	4.5	35
90	Thirty-year cardiovascular risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Australian and New Zealand Journal of Psychiatry, 2019, 53, 651-662.	2.3	31

#	Article	IF	Citations
91	Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Brain, Behavior, and Immunity, 2019, 75, 112-118.	4.1	103
92	Hair cortisol in newly diagnosed bipolar disorder and unaffected first-degree relatives. Psychoneuroendocrinology, 2019, 99, 183-190.	2.7	23
93	Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative. International Journal of Bipolar Disorders, 2019, 7, 20.	2.2	41
94	Neural response to emotional faces in monozygotic twins: association with familial risk of affective disorders. Journal of Psychiatry and Neuroscience, 2019, 44, 277-286.	2.4	4
95	Increased sensitivity to positive social stimuli in monozygotic twins at risk of bipolar vs. unipolar disorder. Journal of Affective Disorders, 2018, 232, 212-218.	4.1	10
96	Leukocytes in peripheral blood in patients with bipolar disorder â€“ Trait and state alterations and association with levels of cytokines and C-reactive protein. Psychiatry Research, 2018, 261, 383-390.	3.3	12
97	Glycogen synthase kinase-3Î² activity and cognitive functioning in patients with bipolar I disorder. European Neuropsychopharmacology, 2018, 28, 361-368.	0.7	4
98	Risk for affective disorders is associated with greater prefrontal gray matter volumes: A prospective longitudinal study. NeuroImage: Clinical, 2018, 17, 786-793.	2.7	13
99	Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial. Trials, 2018, 19, 234.	1.6	7
100	Is negative self-referent bias an endophenotype for depression? An fMRI study of emotional self-referent words in twins at high vs. low risk of depression. Journal of Affective Disorders, 2018, 226, 267-273.	4.1	10
101	Risk of recurrence after a single manic or mixed episode â€“ a systematic review and metaâ€analysis. Bipolar Disorders, 2018, 20, 9-17.	1.9	26
102	Substance use among Danish psychiatric patients: a cross-sectional study. Nordic Journal of Psychiatry, 2018, 72, 130-136.	1.3	11
103	Internet use by older adults with bipolar disorder: international survey results. International Journal of Bipolar Disorders, 2018, 6, 20.	2.2	13
104	Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. Trials, 2018, 19, 611.	1.6	16
105	Mogens Schou (1918â€2005): a scientist, a doctor and a lithium champion. Bipolar Disorders, 2018, 20, 680-682.	1.9	0
106	Clinical Characteristics, Life Adversities and Personality Traits in Monozygotic Twins With, at Risk of and Without Affective Disorders. Frontiers in Psychiatry, 2018, 9, 401.	2.6	11
107	Effect of action-based cognitive remediation on cognition and neural activity in bipolar disorder: study protocol for a randomized controlled trial. Trials, 2018, 19, 487.	1.6	18
108	Does S100B have a potential role in affective disorders? A literature review. Nordic Journal of Psychiatry, 2018, 72, 462-470.	1.3	16

#	Article	IF	Citations
109	Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neuroscience and Biobehavioral Reviews, 2018, 94, 11-16.	6.1	102
110	Towards a biomarker model for cognitive improvement: No change in memory-related prefrontal engagement following a negative cognitive remediation trial in bipolar disorder. Journal of Psychopharmacology, 2018, 32, 1075-1085.	4.0	14
111	Neural correlates of improved recognition of happy faces after erythropoietin treatment in bipolar disorder. Acta Psychiatrica Scandinavica, 2018, 138, 336-347.	4.5	5
112	Effects of erythropoietin on body composition and fatâ€"glucose metabolism in patients with affective disorders. Acta Neuropsychiatrica, 2018, 30, 342-349.	2.1	10
113	Influences of patient informed cognitive complaints on activities of daily living in patients with bipolar disorder. An exploratory cross-sectional study. Psychiatry Research, 2017, 249, 268-274.	3.3	19
114	Differences in neural and cognitive response to emotional faces in middle-aged dizygotic twins at familial risk of depression. Psychological Medicine, 2017, 47, 2345-2357.	4.5	11
115	Sexual distress and quality of life among women with bipolar disorder. International Journal of Bipolar Disorders, 2017, 5, 29.	2.2	18
116	The catecholâ€Oâ€methyltransferase (COMT) Val158Met genotype modulates working memoryâ€related dorsolateral prefrontal response and performance in bipolar disorder. Bipolar Disorders, 2017, 19, 214-224.	1.9	54
117	The search for neuroimaging and cognitive endophenotypes: A critical systematic review of studies involving unaffected first-degree relatives of individuals with bipolar disorder. Neuroscience and Biobehavioral Reviews, 2017, 73, 1-22.	6.1	85
118	Treatment with a GLPâˆ'1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. European Neuropsychopharmacology, 2017, 27, 1153-1162.	0.7	49
119	Increased blood BDNF in healthy individuals with a family history of depression. Psychiatry Research, 2017, 256, 176-179.	3.3	16
120	International multi-site survey on the use of online support groups in bipolar disorder. Nordic Journal of Psychiatry, 2017, 71, 473-476.	1.3	4
121	The Bipolar Illness Onset study: research protocol for the BIO cohort study. BMJ Open, 2017, 7, e015462.	1.9	119
122	Differences in clinical presentation between bipolar I and II disorders in the early stages of bipolar disorder: A naturalistic study. Journal of Affective Disorders, 2017, 208, 521-527.	4.1	26
123	Personalized medicine in psychiatry. Nordic Journal of Psychiatry, 2017, 71, 12-19.	1.3	46
124	Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. Journal of Affective Disorders, 2017, 207, 114-120.	4.1	110
125	Ability to perform Activities of Daily Living among patients with bipolar disorder in remission. Edorium Journal of Disability and Rehabilitation, 2017, 3, 3.	0.3	5
126	Effects of erythropoietin on memoryâ€relevant neurocircuitry activity and recall in mood disorders. Acta Psychiatrica Scandinavica, 2016, 134, 249-259.	4.5	27

#	Article	IF	Citations
127	Glycogen synthase kinaseâ€3Î² in patients with bipolar I disorder: results from a prospective study. Bipolar Disorders, 2016, 18, 334-341.	1.9	8
128	Brainâ€derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course. Bipolar Disorders, 2016, 18, 373-378.	1.9	20
129	Increased DNA and RNA damage by oxidation in patients with bipolar I disorder. Translational Psychiatry, 2016, 6, e867-e867.	4.8	42
130	Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. CNS Spectrums, 2016, 21, 362-366.	1.2	31
131	Neural correlates of improved executive function following erythropoietin treatment in mood disorders. Psychological Medicine, 2016, 46, 1679-1691.	4.5	34
132	Glycogen Synthase Kinase-3Î²: Variation over Time and the Possible Association with Mood and Cognition in Healthy Individuals. Neuropsychobiology, 2016, 73, 108-115.	1.9	5
133	No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial. Acta Neuropsychiatrica, 2016, 28, 101-109.	2.1	6
134	A peripheral composite proteomic and gene expression biomarker related to diagnosis and affective state in rapid cycling bipolar disorder. European Psychiatry, 2016, 33, S123-S123.	0.2	0
135	Unaffected twins discordant for affective disorders show changes in anterior callosal white matter microstructure. Acta Psychiatrica Scandinavica, 2016, 134, 441-451.	4.5	6
136	The effect of erythropoietin on cognition in affective disorders â€“ Associations with baseline deficits and change in subjective cognitive complaints. European Neuropsychopharmacology, 2016, 26, 1264-1273.	0.7	45
137	Online information seeking by patients with bipolar disorder: results from an international multisite survey. International Journal of Bipolar Disorders, 2016, 4, 17.	2.2	35
138	Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. Journal of Affective Disorders, 2016, 205, 378-386.	4.1	110
139	Internet use by patients with bipolar disorder: Results from an international multisite survey. Psychiatry Research, 2016, 242, 388-394.	3.3	36
140	Voice analysis as an objective state marker in bipolar disorder. Translational Psychiatry, 2016, 6, e856-e856.	4.8	167
141	Behavioral activities collected through smartphones and the association with illness activity in bipolar disorder. International Journal of Methods in Psychiatric Research, 2016, 25, 309-323.	2.1	113
142	Effect of recombinant erythropoietin on inflammatory markers in patients with affective disorders: A randomised controlled study. Brain, Behavior, and Immunity, 2016, 57, 53-57.	4.1	22
143	Antiâ€inflammatory agents in the treatment of bipolar depression: a systematic review and metaâ€analysis. Bipolar Disorders, 2016, 18, 89-101.	1.9	153
144	Effect of escitalopram versus placebo on GRÎ± messenger RNA expression in peripheral blood cells of healthy individuals with a family history of depression â€“ a secondary outcome analysis from the randomized AGENDA trial. Nordic Journal of Psychiatry, 2016, 70, 297-302.	1.3	4

#	Article	IF	Citations
145	Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar I disorder â€“ Results from a prospective study. Journal of Affective Disorders, 2016, 197, 167-174.	4.1	67
146	Impaired down-regulation of negative emotion in self-referent social situations in bipolar disorder: A pilot study of a novel experimental paradigm. Psychiatry Research, 2016, 238, 318-325.	3.3	23
147	The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. Therapeutic Advances in Chronic Disease, 2016, 7, 153-159.	2.5	35
148	State-related differences in the level of psychomotor activity in patients with bipolar disorderÂâ€“ Continuous heart rate and movement monitoring. Psychiatry Research, 2016, 237, 166-174.	3.3	27
149	Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis. Molecular Psychiatry, 2016, 21, 216-228.	7.9	120
150	Healthy co-twins of patients with affective disorders show reduced risk-related activation of the insula during a monetary gambling task. Journal of Psychiatry and Neuroscience, 2016, 41, 38-47.	2.4	7
151	Targeting Treatments to Improve Cognitive Function in Mood Disorder. Journal of Clinical Psychiatry, 2016, 77, e1639-e1646.	2.2	37
152	Risk. Impact of having a first-degree relative with affective disorder: a 7-year follow-up study. Danish Medical Journal, 2016, 63, .	0.5	0
153	Daily electronic self-monitoring in bipolar disorder using smartphones â€“ the MONARCA I trial: a randomized, placebo-controlled, single-blind, parallel group trial. Psychological Medicine, 2015, 45, 2691-2704.	4.5	152
154	Smartphone data as an electronic biomarker of illness activity in bipolar disorder. Bipolar Disorders, 2015, 17, 715-728.	1.9	131
155	The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study. PLoS ONE, 2015, 10, e0127629.	2.5	18
156	Effects of Short-Term Cognitive Remediation on Cognitive Dysfunction in Partially or Fully Remitted Individuals with Bipolar Disorder: Results of a Randomised Controlled Trial. PLoS ONE, 2015, 10, e0127955.	2.5	91
157	Electronic monitoring of psychomotor activity as a supplementary objective measure of depression severity. Nordic Journal of Psychiatry, 2015, 69, 118-125.	1.3	16
158	The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder. CNS Drugs, 2015, 29, 577-589.	5.9	113
159	Reduced mRNA Expression of PTGDS in Peripheral Blood Mononuclear Cells of Rapid-Cycling Bipolar Disorder Patients Compared with Healthy Control Subjects. International Journal of Neuropsychopharmacology, 2015, 18, pyu101-pyu101.	2.1	22
160	Mood instability in bipolar disorder type I versus type II-continuous daily electronic self-monitoring of illness activity using smartphones. Journal of Affective Disorders, 2015, 186, 342-349.	4.1	50
161	Assessment of subjective and objective cognitive function in bipolar disorder: Correlations, predictors and the relation to psychosocial function. Psychiatry Research, 2015, 229, 565-571.	3.3	67
162	Different neural and cognitive response to emotional faces in healthy monozygotic twins at risk of depression. Psychological Medicine, 2015, 45, 1447-1458.	4.5	32

#	Article	IF	Citations
163	The Diagnostic Apathia Scale predicts a doseâ€"remission relationship of T-PEMF in treatment-resistant depression. Acta Neuropsychiatrica, 2015, 27, 1-7.	2.1	9
164	Bipolar Patients' Quality of Life in Mixed States: A Preliminary Qualitative Study. Psychopathology, 2015, 48, 192-201.	1.5	11
165	A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder. Translational Psychiatry, 2015, 5, e614-e614.	4.8	58
166	Elevated levels of urinary markers of oxidatively generated DNA and RNA damage in bipolar disorder. Bipolar Disorders, 2015, 17, 257-268.	1.9	51
167	Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders. Biological Psychiatry, 2015, 78, 270-277.	1.3	83
168	Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain, Behavior, and Immunity, 2015, 43, 205-213.	4.1	73
169	Dr Miskowiak and Colleagues Reply. Journal of Clinical Psychiatry, 2015, 76, e835-e836.	2.2	1
170	Daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphonesâ€" the MONARCA II trial protocol: a randomized controlled single-blind parallel-group trial. BMC Psychiatry, 2014, 14, 309.	2.6	82
171	The role of estrogen in bipolar disorder, a review. Nordic Journal of Psychiatry, 2014, 68, 81-87.	1.3	41
172	Dose-remission of pulsating electromagnetic fields as augmentation in therapy-resistant depression: a randomized, double-blind controlled study. Acta Neuropsychiatrica, 2014, 26, 272-279.	2.1	20
173	Serotonin transporter genotype, salivary cortisol, neuroticism and life events: Impact on subsequent psychopathology in healthy twins at high and low risk for affective disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 193-198.	4.8	5
174	Smartphone data as objective measures of bipolar disorder symptoms. Psychiatry Research, 2014, 217, 124-127.	3.3	162
175	Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial. Neuropsychopharmacology, 2014, 39, 1399-1408.	5.4	89
176	Brain Derived Neurotrophic Factor (BDNF) levels as a possible predictor of psychopathology in healthy twins at high and low risk for affective disorder. Psychoneuroendocrinology, 2014, 39, 179-183.	2.7	9
177	Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology, 2014, 47, 199-211.	2.7	45
178	Recombinant Human Erythropoietin to Target Cognitive Dysfunction in Bipolar Disorder. Journal of Clinical Psychiatry, 2014, 75, 1347-1355.	2.2	80
179	Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. Journal of Psychiatric Research, 2013, 47, 1119-1133.	3.1	358
180	P.2.d.033 Erythropoetin as a new treatment for cogntive dysfunction in bipolar disorder?. European Neuropsychopharmacology, 2013, 23, S383.	0.7	0

#	Article	IF	Citations
181	Cytokines in bipolar disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2013, 144, 16-27.	4.1	229
182	Are variations in whole blood BDNF level associated with the BDNF Val66Met polymorphism in patients with first episode depression?. Psychiatry Research, 2013, 210, 102-108.	3.3	14
183	The effect of prolonged duration of untreated depression on antidepressant treatment outcome. Journal of Affective Disorders, 2013, 145, 42-48.	4.1	85
184	Risk markers for affective disorder, a seven-years follow up study of a twin cohort at low and high risk for affective disorder. Journal of Psychiatric Research, 2013, 47, 565-571.	3.1	22
185	Effects of cognitive remediation on cognitive dysfunction in partially or fully remitted patients with bipolar disorder: study protocol for a randomized controlled trial. Trials, 2013, 14, 378.	1.6	29
186	Daily electronic self-monitoring of subjective and objective symptoms in bipolar disorderâ€"the MONARCA trial protocol (MONitoring, treAtment and pRediCtion of bipolAr disorder episodes): a randomised controlled single-blind trial. BMJ Open, 2013, 3, e003353.	1.9	73
187	Designing mobile health technology for bipolar disorder. , 2013, , .		206
188	The Performance of the Revised Major Depression Inventory for Self-Reported Severity of Depression - Implications for the DSM-5 and ICD-11. Psychotherapy and Psychosomatics, 2013, 82, 187-188.	8.8	6
189	Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials. Nordic Journal of Psychiatry, 2013, 67, 369-382.	1.3	23
190	Impairment of Executive Function and Attention Predicts Onset of Affective Disorder in Healthy High-Risk Twins. Journal of Clinical Psychiatry, 2013, 74, e747-e753.	2.2	34
191	Is there a difference in subjective experience of cognitive function in patients with unipolar disorder versus bipolar disorder?. Nordic Journal of Psychiatry, 2012, 66, 389-395.	1.3	27
192	The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depressionâ€"A randomised trial. Psychiatry Research, 2012, 200, 354-360.	3.3	19
193	Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?. Nordic Journal of Psychiatry, 2012, 66, 248-253.	1.3	102
194	Differences in psychomotor activity in patients suffering from unipolar and bipolar affective disorder in the remitted or mild/moderate depressive state. Journal of Affective Disorders, 2012, 141, 457-463.	4.1	71
195	Metabolic syndrome in a cohort of affectively ill patients, a naturalistic study. Nordic Journal of Psychiatry, 2012, 66, 142-145.	1.3	6
196	Stateâ€related alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disorders, 2012, 14, 684-696.	1.9	38
197	Effect of Chronic Escitalopram versus Placebo on Personality Traits in Healthy First-Degree Relatives of Patients with Depression: A Randomized Trial. PLoS ONE, 2012, 7, e31980.	2.5	13
198	Promoter variants in IL18 are associated with onset of depression in patients previously exposed to stressful-life events. Journal of Affective Disorders, 2012, 136, 134-138.	4.1	47

#	Article	IF	Citations
199	Psychometric validation and clinical validity of the Minor Melancholia Mood Checklist (MMCL-32). Journal of Affective Disorders, 2012, 137, 79-86.	4.1	1
200	Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology, 2012, 219, 687-698.	3.1	56
201	Subjective experience of cognitive function in affective disorders. European Psychiatry, 2011, 26, 234-234.	0.2	0
202	Escitalopram and Neuroendocrine Response in Healthy First-Degree Relatives to Depressed Patients â€“ A Randomized Placebo-Controlled Trial. PLoS ONE, 2011, 6, e21224.	2.5	12
203	From items to syndromes in the Hypomania Checklist (HCL-32): Psychometric validation and clinical validity analysis. Journal of Affective Disorders, 2011, 132, 48-54.	4.1	43
204	A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression. Therapeutic Advances in Psychopharmacology, 2011, 1, 133-144.	2.7	8
205	Differences Between Early and Late Onset Adult Depression. Clinical Practice and Epidemiology in Mental Health, 2011, 7, 140-147.	1.2	55
206	Coping Styles in Healthy Individuals at Risk of Affective Disorder. Journal of Nervous and Mental Disease, 2010, 198, 39-44.	1.0	8
207	Does bereavement-related first episode depression differ from other kinds of first depressions?. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 801-808.	3.1	27
208	Hippocampal volume changes in healthy subjects at risk of unipolar depression. Journal of Psychiatric Research, 2010, 44, 655-662.	3.1	70
209	Salivary cortisol in depressed patients versus control persons: A systematic review and meta-analysis. Psychoneuroendocrinology, 2010, 35, 1275-1286.	2.7	247
210	Clinical utility of Standardised Assessment of Personality â€" Abbreviated Scale (SAPAS) among patients with first episode depression. Journal of Affective Disorders, 2010, 127, 199-202.	4.1	27
211	Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials, 2010, 11, 97.	1.6	42
212	Familial Risk for Mood Disorder and the Personality Risk Factor, Neuroticism, Interact in Their Association with Frontolimbic Serotonin 2A Receptor Binding. Neuropsychopharmacology, 2010, 35, 1129-1137.	5.4	49
213	Gender Differences among Patients with a Single Depressive Episode. Psychopathology, 2010, 43, 159-169.	1.5	13
214	The Influence of Comorbid Personality Disorder and Neuroticism on Treatment Outcome in First Episode Depression. Psychopathology, 2010, 43, 197-204.	1.5	41
215	Variations in 5-HTTLPR: Relation to familiar risk of affective disorder, life events, neuroticism and cortisol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 86-91.	4.8	16
216	No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment. European Neuropsychopharmacology, 2010, 20, 327-335.	0.7	31

#	Article	IF	Citations
217	Validity of the diagnosis of a single depressive episode in a case register. Clinical Practice and Epidemiology in Mental Health, 2009, 5, 4.	1.2	161
218	The BDNF Val66Met polymorphism: Relation to familiar risk of affective disorder, BDNF levels and salivary cortisol. Psychoneuroendocrinology, 2009, 34, 1380-1389.	2.7	46
219	Interaction between genetic polymorphisms and stressful life events in first episode depression. Journal of Affective Disorders, 2009, 119, 107-115.	4.1	84
220	Do stressful life events predict medical treatment outcome in first episode of depression?. Social Psychiatry and Psychiatric Epidemiology, 2009, 44, 752-760.	3.1	20
221	Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first degree relatives of persons with depression. Trials, 2009, 10, 66.	1.6	13
222	High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. NeuroImage, 2009, 46, 360-366.	4.2	50
223	Whole blood BDNF levels in healthy twins discordant for affective disorder: Association to life events and neuroticism. Journal of Affective Disorders, 2008, 108, 165-169.	4.1	30
224	Salivary cortisol in unaffected twins discordant for affective disorder. Psychiatry Research, 2008, 161, 292-301.	3.3	30
225	Measurements of brain-derived neurotrophic factor: Methodological aspects and demographical data. Brain Research Bulletin, 2007, 73, 143-149.	3.0	178
226	Attention to side effects enhances medical adherence. Acta Psychiatrica Scandinavica, 2007, 115, 82-82.	4.5	4
227	Personality traits in unaffected twins discordant for affective disorder. Acta Psychiatrica Scandinavica, 2007, 115, 442-450.	4.5	16
228	Quality of life in unaffected twins discordant for affective disorder. Journal of Affective Disorders, 2007, 99, 133-138.	4.1	4
229	Do personality traits predict first onset in depressive and bipolar disorder?. Nordic Journal of Psychiatry, 2006, 60, 79-88.	1.3	73
230	Cognitive function in unaffected twins discordant for affective disorder. Psychological Medicine, 2006, 36, 1119-1129.	4.5	107
231	Neural responses during down-regulation of negative emotion in patients with recently diagnosed bipolar disorder and their unaffected relatives. Psychological Medicine, 0, , 1-12.	4.5	1
232	Emotional cognition subgroups in unaffected first-degree relatives of patients with mood disorders. Psychological Medicine, 0, , 1-11.	4.5	1
233	Pharmacological Treatment of Individuals at Familial Risk for Bipolar or Major Depressive Disorders: a Scoping Review. Current Treatment Options in Psychiatry, 0, , 1.	1.9	0